ClinicalTrials.gg
CompletedNCT01821378Updated Jul 21, 2016Results posted

Lurasidone Low-Dose - High-Dose Study Study

A Phase 3 interventional study of Lurasidone and Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2 in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 66 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-07-21.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
9th of 39
412 · median 149
Started
2013
with 4 others
Phase 3
18 of 39
none open now
Registered
25th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 9th largest by enrollment, is one of 5 that started in 2013, is one of 18 in phase 3, and was the 25th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of lurasidone 20 mg/day in subjects with an acute exacerbation of schizophrenia.

Read the detailed description

The primary purpose of this study is to evaluate the efficacy of lurasidone 20 mg/day in subjects with an acute exacerbation of schizophrenia. This study will also evaluate the efficacy and safety of lurasidone 80 mg/day and160 mg/day versus placebo in subjects who are early non-responders (operationally defined per protocol) to lurasidone 80 mg/day.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Lurasidone
  • Latuda
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject provides written and is willing and able to comply with the protocol in the opinion of the Investigator.

  • Subject is ≥ 18 and ≤ 75 years of age, on the day of signing the informed consent.
  • Subject meets criteria for a primary diagnosis of schizophrenia [including disorganized (295.10), paranoid (295.30), undifferentiated (295.90) subtypes] as established by clinical interview (using the DSM-IV-TR as a reference and confirmed using the SCID-CT). The duration of the subject's illness whether treated or untreated must be ≥ 6 months.
  • Subject has a PANSS total score ≥ 80 and a PANSS subscale score ≥ 4 (moderate) on 2 or more of the following PANSS subscale items: delusions, conceptual disorganization, hallucinations, and unusual thought content at screening and baseline.
  • Subject has a CGI-S score of ≥ 4 at screening and baseline.
  • Subject has an acute exacerbation of psychotic symptoms (no longer than 2 months) and marked deterioration of function from baseline (by history) or subject has been hospitalized for the purpose of treating an acute psychotic exacerbation for 2 consecutive weeks or less immediately before screening.

Subjects who have been hospitalized for more than 2 weeks for reasons unrelated to acute exacerbation can be included with concurrence from the Medical Monitor that such hospitalization was for a reason other than acute relapse. For example, subjects in a long term hospital setting who have an acute exacerbation and are transferred to an acute unit are eligible for study entry.

  • Subject is not pregnant (must have a negative serum pregnancy test at screening) or nursing (must not be lactating) and is not planning pregnancy within the projected duration of the study.
  • Female subject of agrees to remain abstinent or use adequate and reliable throughout the study and for at least 30 days after the last dose of lurasidone has been taken. In the Investigator's judgment, the subject will adhere to this requirement.

Adequate contraception is defined as continuous use of either two barrier methods (eg, condom and spermicide or diaphragm with spermicide) or a hormonal contraceptive. Acceptable hormonal contraceptives include the following: a) contraceptive implant (such as Norplant®) implanted at least 90 days prior to screening; b) injectable contraception (such as medroxyprogesterone acetate injection) given at least 14 days prior to screening; or c) oral contraception taken as directed for at least 30 days prior to screening.

Subjects who are of non-reproductive potential, ie, subject who is surgically sterile, has undergone tubal ligation, or is (defined as at least 12 months of spontaneous amenorrhea or between 6 and 12 months of spontaneous amenorrhea with follicle stimulating hormone (FSH) concentrations within postmenopausal range as determined by laboratory analysis) are not required to remain abstinent or use adequate contraception.

  • Subject is able and agrees to remain off prior antipsychotic medication for the duration of the study
  • Subject has had a stable living arrangement at the time of screening and agrees to return to a similar living arrangement after discharge. This criterion is not meant to exclude subjects who have temporarily left a stable living arrangement (eg, due to psychosis). Such subjects remain eligible to participate in this protocol. Chronically homeless subjects should not be enrolled.
  • Subject is in good physical health on the basis of medical history, physical examination, and laboratory screening.
  • Subject who requires concomitant medication treatment with the following agents may be included if they have been on stable doses (ie, minor adjustments only) for the specified times: 1) oral hypoglycemics must be stable for at least 30 days prior to screening, 2) antihypertensive agents must be stable for at least 30 days prior to screening, and 3) thyroid hormone replacement must be stable for at least 90 days prior to screening. (Note: inducers and inhibitors will not be allowed).
  • Subject is willing and able to comply with the protocol assessments and visits, in the opinion of the study nurse/coordinator and the Investigator.

Exclusion criteria

Exclusion Criteria:

Subject has a Axis I or Axis II diagnosis, other than schizophrenia, that has been the primary focus of treatment within 3 months of screening.

  • Subject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at screening (ie, in the past one month) or baseline (ie, since last visit).
  • Subject is considered by the Investigator to be at imminent risk of suicide or injury to self, others, or property.
  • Subject has attempted suicide within 3 months prior to the screening phase.
  • Subject currently has a medical condition including the following: neurological, metabolic (including Type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, and/or urological disorder such as unstable angina, congestive heart failure (uncontrolled), or central nervous system (CNS) infection that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study. Subjects with known (HIV) seropositivity will be excluded.

Note:Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Monitor should be consulted. Any subject with a known cardiovascular disease or condition (even if controlled) must be discussed with the Medical Monitor during screening.

  • Subject has evidence of any chronic organic disease of the CNS such as tumors, inflammation, and active seizure disorder, vascular disorder, Parkinson's disease, Alzheimer's disease or other forms of dementia, myasthenia gravis, or other degenerative processes. In addition, subject must not have a history of mental retardation or persistent neurological symptoms attributable to serious head injury. Note: Past history of febrile seizures, drug-induced seizures, or alcohol withdrawal seizures is not exclusionary.
  • Subject demonstrates evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation.

Note: Subjects with serum (ALT) or aspartate transaminase (AST) levels greater than or equal to 3 times the upper limit of the reference ranges provided by the central laboratory require retesting. If on retesting the laboratory value remain greater than or equal to 3 times the upper limit, the subject will be excluded.

  • Subject has a history of stomach or intestinal surgery or any other condition that could interfere with or is judged by the Investigator to interfere with absorption, distribution, metabolism, or excretion of study drug.
  • Subject with Type 1 or Type 2 insulin-dependent diabetes.
  • Subject with newly diagnosed Type 2 diabetes during screening. Subject with Type 2 diabetes is eligible for study inclusion if the following condition is met at screening:

if a subject is currently being treated with oral anti-diabetic medication(s), the dose must have been stable for at least 4 weeks prior to screening. Such medication may be adjusted or discontinued during the study, as clinically indicated.

-Subject has any abnormal laboratory parameter at screening that indicates a clinically significant medical condition as determined by the Investigator. Subjects with a fasting blood glucose at screening ≥ 126 mg/dL (7.0 mmol/L) or ≥ 6.5% will be excluded.

Note: Subjects with random (non-fasting) blood glucose at screening ≥ 200 mg/dL (11.1 mmol/L) must be retested in a fasted state.

  • Subject has a prolactin concentration > 100 ng/mL at screening or has a history of pituitary adenoma.
  • Subject has a history of \< 5 years prior to signing the , except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Pituitary tumors of any duration are excluded.
  • Subject is judged to be resistant to antipsychotic treatment defined as any one of the following:

    1. failure to respond to > 2 marketed antipsychotic agents, given at an adequate dose and for an adequate duration (within the past 2 years)
    2. history of treatment with clozapine for psychosis
  • Subject is receiving an antipsychotic medication above the maximum recommended (country-specific) dose at or prior to screening and, in the judgment of the Investigator, is unlikely to respond to standard doses of lurasidone.
  • Subject has received depot antipsychotics unless the last injection was at least one treatment cycle or at least 30 days (whichever is longer), prior to the screening phase.
  • Subject has received treatment with antidepressants within 7 days (fluoxetine hydrochloride within 28 days, MAO inhibitors within 14 days) or clozapine within 120 days prior to the double-blind baseline.
  • Subject requires treatment with any potent inhibitors or inducers during the study (Appendix 3).
  • Subject has received electroconvulsive therapy treatment within the 3 months prior to screening or is expected to require ECT during the study.
  • Subject has a history of neuroleptic malignant syndrome.
  • Subject exhibits evidence of severe tardive dyskinesia, severe dystonia, or any other severe movement disorder. Severity will be determined by the Investigator.
  • Subject has a history of alcohol or substance abuse (DSM-IV-TR criteria) within 3 months prior to screening or alcohol or substance dependence (DSM-IV-TR criteria) within 12 months prior to screening. The only exceptions include caffeine or nicotine abuse/dependence.
  • Subject tests positive for drugs of abuse at screening, however, a positive test for amphetamines, barbiturates, opiates, benzodiazepines or methadone may not result in exclusion of subjects if the investigator determines that the positive test is as a result of prescription medicine(s). In the event a subject tests positive for cannabinoids (tetrahydrocannabinol), the Investigator will evaluate the subject's ability to abstain from using this substance during the study. This information will be discussed with the Medical Monitor prior to study enrollment.
  • Subject had a history or presence of an abnormal (ECG), which in the Investigator's opinion is clinically significant (Medical Monitor may be consulted to determine clinical significance).
  • Subject has poor peripheral venous access that will limit the ability to draw blood as judged by the Investigator.
  • Subject has a history of to more than 2 distinct chemical classes of drug (eg, sulfas and penicillins).
  • Subject was screened or washed out previously more than three times for this study.
  • Subject is currently participating, or has participated in, a study with an or marketed compound or device within 3 months prior to signing the informed consent, or has participated in 2 or more studies within 12 months prior to signing the informed consent.
  • Subject is homeless or did not have a stable residence for the 3 months prior to the screening phase.
  • Subject is unable to cooperate with any study procedures, unlikely to adhere to the study procedures and keep appointments, in the opinion of the Investigator, or was planning to relocate during the study.
  • Subject demonstrates a decrease (improvement) of ≥ 20% in the PANSS total score between screening and baseline visits (use Appendix 6 for calculation), or the PANSS total score falls below 80 at baseline.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
412 participants (actual)

Study arms

  • Experimental
    Lurasidone 20 mg

    Lurasidone 20 mg once daily

    Drug: Lurasidone · Drug: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2 · Drug: Placebo

  • Experimental
    Lurasidone 80 mg

    Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2

    Drug: Lurasidone · Drug: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2 · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo Comparator 20 or 80 mg once daily

    Drug: Lurasidone · Drug: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2 · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 for Lurasidone 20 mg and 80-160 mg Versus Placebo.

    The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

    Time frame: Baseline to 6 Weeks

Secondary outcomes

  1. Change in Clinical Global Impression-Severity of Illness (CGI-S) Score at Week 6 for Lurasidone 20 mg and 80-160 mg Versus Placebo.

    The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale (0-7), where a higher score is associated with greater illness severity. Following a clinical interview, the CGI-S can be completed in 1-2 minutes.

    Time frame: Baseline to 6 Weeks

  2. Change From Baseline to Week 6 for the Lurasidone 20 mg, and Lurasidone 80 - 160 mg Groups Versus the Placebo Group in the Montgomery-Asberg Depression Rating Scale Total Score

    The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.

    Time frame: Baseline to 6 Weeks

  3. Proportion of Subjects Who Achieve a Response, Defined as 20% or Greater Improvement From Baseline in Positive and Negative Syndrome Score (PANSS) Total Score at Week 6

    The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

    Time frame: 6 Weeks

  4. Change From Week 2 to Week 6 for the ENR (Early Non-responders) Lurasidone 160mg Group vs the ENR (Early Non-responders) Lurasidone 80 mg Group in the Following: PANSS Total Score

    The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

    Time frame: week 2 to week 6

  5. Change From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the MADRS Total Score

    The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.

    Time frame: baseline to week 6

  6. Change From Week 2 to Week 6 for ENR Lurasidone 80 mg vs. ENR Lurasidone 160 mg in CGI-S Score

    The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale (0-7), where a higher score is associated with greater illness severity. Following a clinical interview, the CGI-S can be completed in 1-2 minutes.

    Time frame: week 2 to week 6

  7. Change From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the PANSS Total Score

    The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

    Time frame: Baseline to week 6

  8. Change From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the CGI-S Score

    The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale, where a higher score is associated with greater illness severity. Following a clinical interview, the CGI-S can be completed in 1-2 minutes. Reason for the discrepancy of the LS mean (SE) for placebo in outcome 2 and outcome 9 is because the different MMRM model used in outcome 2 and outcome 9. The treatment groups included in the MMRM model for outcome 2 are placebo, lurasidone 20 mg, and lurasidone 80-160 mg. The treatment groups included in the MMRM model for outcome 9 are placebo, ENR lurasidone 80 mg, and ENR lurasidone 160 mg.

    Time frame: baseline to week 6

Other outcomes

  1. Change From Baseline to Week 6 for the Lurasidone 20 mg and Lurasidone 80 - 160 mg Groups Compared to the Placebo Group in the GAF Score

    The GAF is a numeric scale (0 through 100) that measures a patient's overall level of psychological, social, and occupation functioning. It is designed to guide clinicians through a methodical and comprehensive consideration of all aspects of a patient's symptoms and functioning. The scale begins at 100 - superior functioning - to 0 - inadequate information.

    Time frame: 6 Weeks

  2. Change From Baseline to Week 6 for the Lurasidone 20 mg and Lurasidone 80 - 160 mg Groups Compared to the Placebo Group in the Euroqol (EQ-5D) Index Score

    The EQ-5D is a standardized measure of health state consisting of two parts: a) EQ-5D measuring mobility, self-care, pain/discomfort, usual activities, and anxiety/depression on a 0 2 scale with lower scores indicating improvement, and b) a 20-cm visual analogue scale (VAS) for health status rating on a 0-100 scale with higher scores indicating improvement. EQ-5D health states, defined by the EQ-5D descriptive system, may be converted into a single summary index (i.e. the EQ-5D index score) by applying a formula that essentially attaches values (also called weights) to each of the levels in each dimension. The EQ-5D Index scores ranged from -0.429 to 1.000. Generally higher observed EQ-5D Index scores indicate a better degree of health.

    Time frame: 6 weeks

07

Results

Posted Jan 8, 2016

Participant flow

Participant flow — Overall Study
MilestoneLurasidone 20 mgLurasidone 80 mg - 160 mgPlacebo
Started101199112
Completed7414570
Not completed275442

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 for Lurasidone 20 mg and 80-160 mg Versus Placebo.

The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Time frame:
Baseline to 6 Weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 for Lurasidone 20 mg and 80-160 mg Versus Placebo.
units on a scaleLurasidone 20 mgLurasidone 80-160 mgPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 for Lurasidone 20 mg and 80-160 mg Versus Placebo.-17.6 ± 1.93-24.9 ± 1.40-14.5 ± 1.89
Statistical analysis
  • Lurasidone 20 mg vs Placebo · Mixed Models Analysis · p = 0.255 · Least square mean difference: -3.1 · 95% CI -8.4 to 2.2
  • Lurasidone 80-160 mg vs Placebo · Mixed Models Analysis · p = <-0.001 · Least square mean difference: -10.3 · 95% CI -14.9 to -5.7
SecondaryChange in Clinical Global Impression-Severity of Illness (CGI-S) Score at Week 6 for Lurasidone 20 mg and 80-160 mg Versus Placebo.

The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale (0-7), where a higher score is associated with greater illness severity. Following a clinical interview, the CGI-S can be completed in 1-2 minutes.

Time frame:
Baseline to 6 Weeks
Reported as:
Least squares mean · units on a scale
Change in Clinical Global Impression-Severity of Illness (CGI-S) Score at Week 6 for Lurasidone 20 mg and 80-160 mg Versus Placebo.
units on a scaleLurasidone 20 mgLurasidone 80-160 mgPlacebo
Change in Clinical Global Impression-Severity of Illness (CGI-S) Score at Week 6 for Lurasidone 20 mg and 80-160 mg Versus Placebo.-0.93 ± 0.105-1.30 ± 0.076-0.73 ± 0.103
Statistical analysis
  • Lurasidone 20 mg vs Placebo · Mixed Models Analysis · p = 0.169 · Least square mean difference: -0.20 · 95% CI -0.49 to 0.09
  • Lurasidone 80-160 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Least square mean difference: -0.57 · 95% CI -0.83 to -0.32
SecondaryChange From Baseline to Week 6 for the Lurasidone 20 mg, and Lurasidone 80 - 160 mg Groups Versus the Placebo Group in the Montgomery-Asberg Depression Rating Scale Total Score

The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.

Time frame:
Baseline to 6 Weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 for the Lurasidone 20 mg, and Lurasidone 80 - 160 mg Groups Versus the Placebo Group in the Montgomery-Asberg Depression Rating Scale Total Score
units on a scaleLurasidone 20 mgLurasidone 80-160 mgPlacebo
Change From Baseline to Week 6 for the Lurasidone 20 mg, and Lurasidone 80 - 160 mg Groups Versus the Placebo Group in the Montgomery-Asberg Depression Rating Scale Total Score-2.0 ± 0.57-3.7 ± 0.41-1.7 ± 0.53
Statistical analysis
  • Lurasidone 20 mg vs Placebo · ANCOVA · p = 0.706 · Least square mean difference: -0.3 · 95% CI -1.8 to 1.2
  • Lurasidone 80-160 mg vs Placebo · ANCOVA · p = 0.003 · Least square mean difference: -2.0 · 95% CI -3.3 to -0.7
SecondaryProportion of Subjects Who Achieve a Response, Defined as 20% or Greater Improvement From Baseline in Positive and Negative Syndrome Score (PANSS) Total Score at Week 6

The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Time frame:
6 Weeks
Reported as:
Number · percentage of participants
Proportion of Subjects Who Achieve a Response, Defined as 20% or Greater Improvement From Baseline in Positive and Negative Syndrome Score (PANSS) Total Score at Week 6
percentage of participantsLurasidone 20 mgLurasidone 80-160 mgPlacebo
Proportion of Subjects Who Achieve a Response, Defined as 20% or Greater Improvement From Baseline in Positive and Negative Syndrome Score (PANSS) Total Score at Week 6445373
Statistical analysis
  • Lurasidone 20 mg vs Placebo · Regression, Logistic · p = 0.173 · Odds ratio (or): 1.5 · 95% CI 0.8 to 2.5
  • Lurasidone 80-160 mg vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.2 · 95% CI 2.0 to 5.2
SecondaryChange From Week 2 to Week 6 for the ENR (Early Non-responders) Lurasidone 160mg Group vs the ENR (Early Non-responders) Lurasidone 80 mg Group in the Following: PANSS Total Score

The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Time frame:
week 2 to week 6
Reported as:
Least squares mean · units on a scale
Change From Week 2 to Week 6 for the ENR (Early Non-responders) Lurasidone 160mg Group vs the ENR (Early Non-responders) Lurasidone 80 mg Group in the Following: PANSS Total Score
units on a scaleENR Lurasidone 80 mgENR Lurasidone 160 mg
Change From Week 2 to Week 6 for the ENR (Early Non-responders) Lurasidone 160mg Group vs the ENR (Early Non-responders) Lurasidone 80 mg Group in the Following: PANSS Total Score-8.9 ± 2.20-16.6 ± 2.47
Statistical analysis
  • ENR Lurasidone 80 mg vs ENR Lurasidone 160 mg · Mixed Models Analysis · p = 0.023 · Least square mean difference: -7.7 · 95% CI -14.3 to -1.1
SecondaryChange From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the MADRS Total Score

The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.

Time frame:
baseline to week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the MADRS Total Score
units on a scaleENR Lurasidone 80 mgENR Lurasidone 160 mgPlacebo
Change From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the MADRS Total Score-2.5 ± 0.89-3.5 ± 1.00-1.7 ± 0.59
Statistical analysis
  • ENR Lurasidone 80 mg vs Placebo · ANCOVA · p = 0.464 · Least square mean difference: -0.8 · 95% CI -2.9 to 1.3
  • ENR Lurasidone 160 mg vs Placebo · ANCOVA · p = 0.122 · Least square mean difference: -1.8 · 95% CI -4.1 to 0.5
Other pre-specifiedChange From Baseline to Week 6 for the Lurasidone 20 mg and Lurasidone 80 - 160 mg Groups Compared to the Placebo Group in the GAF Score

The GAF is a numeric scale (0 through 100) that measures a patient's overall level of psychological, social, and occupation functioning. It is designed to guide clinicians through a methodical and comprehensive consideration of all aspects of a patient's symptoms and functioning. The scale begins at 100 - superior functioning - to 0 - inadequate information.

Time frame:
6 Weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 for the Lurasidone 20 mg and Lurasidone 80 - 160 mg Groups Compared to the Placebo Group in the GAF Score
units on a scaleLurasidone 20 mgLurasidone 80-160 mgPlacebo
Change From Baseline to Week 6 for the Lurasidone 20 mg and Lurasidone 80 - 160 mg Groups Compared to the Placebo Group in the GAF Score11.5 ± 1.4315.8 ± 1.049.2 ± 1.40
Statistical analysis
  • Lurasidone 20 mg vs Placebo · Mixed Models Analysis · p = 0.258 · Least square mean difference: 2.3 · 95% CI -1.7 to 6.2
  • Lurasidone 80-160 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Slope: 6.6 · 95% CI 3.2 to 10.1
SecondaryChange From Week 2 to Week 6 for ENR Lurasidone 80 mg vs. ENR Lurasidone 160 mg in CGI-S Score

The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale (0-7), where a higher score is associated with greater illness severity. Following a clinical interview, the CGI-S can be completed in 1-2 minutes.

Time frame:
week 2 to week 6
Reported as:
Least squares mean · units on a scale
Change From Week 2 to Week 6 for ENR Lurasidone 80 mg vs. ENR Lurasidone 160 mg in CGI-S Score
units on a scaleENR Lurasidone 80 mgENR Lurasidone 160 mg
Change From Week 2 to Week 6 for ENR Lurasidone 80 mg vs. ENR Lurasidone 160 mg in CGI-S Score-0.61 ± 0.116-0.96 ± 0.134
Statistical analysis
  • ENR Lurasidone 80 mg vs ENR Lurasidone 160 mg · Mixed Models Analysis · p = 0.052 · Least square mean difference: -0.35 · 95% CI -0.70 to 0.00
Other pre-specifiedChange From Baseline to Week 6 for the Lurasidone 20 mg and Lurasidone 80 - 160 mg Groups Compared to the Placebo Group in the Euroqol (EQ-5D) Index Score

The EQ-5D is a standardized measure of health state consisting of two parts: a) EQ-5D measuring mobility, self-care, pain/discomfort, usual activities, and anxiety/depression on a 0 2 scale with lower scores indicating improvement, and b) a 20-cm visual analogue scale (VAS) for health status rating on a 0-100 scale with higher scores indicating improvement. EQ-5D health states, defined by the EQ-5D descriptive system, may be converted into a single summary index (i.e. the EQ-5D index score) by applying a formula that essentially attaches values (also called weights) to each of the levels in each dimension. The EQ-5D Index scores ranged from -0.429 to 1.000. Generally higher observed EQ-5D Index scores indicate a better degree of health.

Time frame:
6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 for the Lurasidone 20 mg and Lurasidone 80 - 160 mg Groups Compared to the Placebo Group in the Euroqol (EQ-5D) Index Score
units on a scaleLurasidone 20 mgLurasidone 80-160 mgPlacebo
Change From Baseline to Week 6 for the Lurasidone 20 mg and Lurasidone 80 - 160 mg Groups Compared to the Placebo Group in the Euroqol (EQ-5D) Index Score0.041 ± 0.0240.095 ± 0.018-0.042 ± 0.023
Statistical analysis
  • Lurasidone 20 mg vs Placebo · ANCOVA · p = 0.012 · Least square mean difference: 0.084 · 95% CI 0.018 to 0.149
  • Lurasidone 80-160 mg vs Placebo · ANCOVA · p = <0.001 · Least square mean difference: 0.138 · 95% CI 0.081 to 0.194
SecondaryChange From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the PANSS Total Score

The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Time frame:
Baseline to week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the PANSS Total Score
units on a scaleENR Lurasidone 80 mgENR Lurasidone 160 mgPlacebo
Change From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the PANSS Total Score-14.4 ± 2.69-21.7 ± 3.00-14.4 ± 1.98
Statistical analysis
  • ENR Lurasidone 80 mg vs Placebo · Mixed Models Analysis · p = 0.992 · Least square mean difference: -0.00 · 95% CI -6.6 to 6.6
  • ENR Lurasidone 160 mg vs Placebo · Mixed Models Analysis · p = 0.044 · Least square mean difference: -7.3 · 95% CI -14.4 to -0.2
SecondaryChange From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the CGI-S Score

The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale, where a higher score is associated with greater illness severity. Following a clinical interview, the CGI-S can be completed in 1-2 minutes. Reason for the discrepancy of the LS mean (SE) for placebo in outcome 2 and outcome 9 is because the different MMRM model used in outcome 2 and outcome 9. The treatment groups included in the MMRM model for outcome 2 are placebo, lurasidone 20 mg, and lurasidone 80-160 mg. The treatment groups included in the MMRM model for outcome 9 are placebo, ENR lurasidone 80 mg, and ENR lurasidone 160 mg.

Time frame:
baseline to week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the CGI-S Score
units on a scaleENR Lurasidone 80 mgENR Lurasidone 160 mgPlacebo
Change From Baseline to Week 6 for the ENR Lurasidone 80mg and ENR Lurasidone 160mg Groups vs the Placebo in the CGI-S Score-0.83 ± 0.143-1.31 ± 0.160-0.73 ± 0.106
Statistical analysis
  • ENR Lurasidone 80 mg vs Placebo · Mixed Models Analysis · p = 0.578 · Least square mean difference: -0.10 · 95% CI -0.45 to 0.25
  • ENR Lurasidone 160 mg vs Placebo · Mixed Models Analysis · p = 0.003 · Least square mean difference: -0.58 · 95% CI -0.96 to -0.20

Adverse events

Collected over 6 Weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone 20 mg—3/101 (3%)43/101 (42.6%)
Lurasidone 80-160 mg—6/198 (3%)92/198 (46.5%)
Placebo—8/112 (7.1%)58/112 (51.8%)
Most frequent serious events
Most frequent serious events
EventLurasidone 20 mgLurasidone 80-160 mgPlacebo
SchizophreniaPsychiatric disorders3/1013/1984/112
Psychotic DisorderPsychiatric disorders0/1012/1983/112
Therapuetuc Response DelayedGeneral disorders0/1010/1981/112
FallInjury, poisoning and procedural complications0/1011/1980/112
Fibula FractureInjury, poisoning and procedural complications0/1011/1980/112
Tibia FractureInjury, poisoning and procedural complications0/1011/1980/112
Most frequent other events
Showing 10 of 18
Most frequent other events
EventLurasidone 20 mgLurasidone 80-160 mgPlacebo
InsomniaPsychiatric disorders16/10121/19824/112
AkathisiaNervous system disorders5/10121/1982/112
HeadacheNervous system disorders10/10111/1988/112
AgitationPsychiatric disorders5/1019/19811/112
NauseaGastrointestinal disorders2/10117/1984/112
AnxietyPsychiatric disorders8/1018/1987/112
VomitingGastrointestinal disorders0/10111/1981/112
SomnolenceNervous system disorders5/1016/1986/112
DiarrhoeaGastrointestinal disorders2/1018/1983/112
Back PainMusculoskeletal and connective tissue disorders4/1013/1981/112

Baseline characteristics

Safety population: subjects randomized and took at least one dose of study medication (there was one subject was randomized but did not take study medication).

Age, Categorical
Age, Categorical(Participants)Lurasidone 20 mgLurasidone 80-160 mgPlaceboTotal
<=18 years0404
Between 18 and 65 years99192112403
>=65 years2204
Age, Continuous
Age, Continuous(years)Lurasidone 20 mgLurasidone 80-160 mgPlaceboTotal
Mean41.5 ± 10.9640.5 ± 11.4440.7 ± 11.5840.8 ± 11.34
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone 20 mgLurasidone 80-160 mgPlaceboTotal
Female367934149
Male6511978262
Region of Enrollment
Region of Enrollment(participants)Lurasidone 20 mgLurasidone 80-160 mgPlaceboTotal
Colombia39719
Russian Federation23492799
Romania22381878
United States315938128
Ukraine16311360
Slovakia612927
08

Study locations

66 sites
  • Woodland International Research Group, Inc.
    Little Rock, Arkansas 72211, United States
  • Comprehensive Clinical Development
    Cerritos, California 90703, United States
  • Synergy Clinical Research of Escondido
    Escondido, California 92025, United States
  • Apostle Clinical Trials, Inc.
    Long Beach, California 90813, United States
  • Cnri, Llc
    Los Angeles, California 90660, United States
  • Pasadena Research Institute
    Pasadena, California 91106, United States
  • Cnri, Llc
    San Diego, California 92102, United States
  • University of California San Diego Medical Center
    San Diego, California 92103, United States
  • Collaborative Neuroscience Network, Inc.
    Torrance, California 90502, United States
  • Western Affiliated Research Institute
    Denver, Colorado 80209, United States
  • Florida Clinical Research Center, LLC - PARENT
    Maitland, Florida 32751, United States
  • University of Miami Medical Center
    Miami, Florida 33136, United States
  • Florida Clinical Research Center, LLC
    Orlando, Florida 32810, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Via Christi Research, a division of Via Christi Hospitals Wichita, Inc.
    Wichita, Kansas 67214, United States
  • Lake Charles Clinical Trials, LLC
    Lake Charles, Louisiana 70629, United States
  • Center for Behavioral Health, LLC
    Rockville, Maryland 20850, United States
  • St. Charles Psychiatric Associates
    St. Charles, Missouri 63301, United States
  • Midwest Research Group
    St. Charles, Missouri 63304, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • Comprehensive Clinical Development- Holliswood Hospital
    Holliswood, New York 11423, United States
  • Midwest Clinical Research Center, LLC
    Dayton, Ohio 45417, United States
  • CRILifetree
    Philadelphia, Pennsylvania 19139, United States
  • FutureSearch Clinical Trials, L.P.
    Austin, Texas 78731, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Pillar Clinical Research, LLC
    Dallas, Texas 75243, United States
  • Bayou Clinical Research, Ltd.
    Houston, Texas 77007, United States
  • E.S.E. Hospital Mental de Antioquia
    Bello, Colombia
  • Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda
    Bogota, Colombia
  • Instituto Colombiano del Sistema Nervioso - Clinica Montserrat
    Bogota, Colombia
  • Spitalul Universitar de Urgenta Militar Central "Dr Carol Davila"
    Bucuresti, 010825, Romania
  • Spitalul de Psihiatrie Titan "Dr Constantin Gorgos"
    Bucuresti, 030442, Romania
  • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
    Bucuresti, 041914, Romania
  • Spitalul Clinic de Neuropsihiatrie Craiova
    Craiova, 200473, Romania
  • Spitalul Judetean de Urgenta "Sf. Pantelimon" Focsani
    Focsani, 620165, Romania
  • Spitalul de Psihiatrie "Elisabeta Doamna"
    Galati, 800179, Romania
  • Spitalul Clinic de Psihiatrie Socola
    Iasi, 700282, Romania
  • Spitalul Judetean de Urgenta Pitesti
    Pitesti, 110069, Romania
  • Spitalul Judetean de Urgenta Targoviste
    Targoviste, 130086, Romania
  • SHI Arkhangelsk Regional Clinical Psychiatric Hospital
    Arkhangelsk, 163530, Russian Federation
  • SHI Reg Clinical Specialized Psychoneurological Hospital #1
    Chelyabinsk, Russian Federation
  • Kemerovo Regional Clinical Psychiatric Hospital
    Kemerovo, 650036, Russian Federation
  • GUZ Lipetsk Regional psychoneurological Hospital #1
    Lipetsk region, 399313, Russian Federation
  • Moscow Region Psychiatric Hospital #5
    Moscow Region, 142601, Russian Federation
  • SBHI "Samara Psychiatric Clinic"
    Samara, 443016, Russian Federation
  • MHI City Clinical Hospital #2 named after V.I. Razumovsky
    Saratov, 410028, Russian Federation
  • FSBI "Bekhterev Psychoneurological Research Institute SPb Russia"
    St Petersburg, 192019, Russian Federation
  • City Psychiatric Hospital of St. Nikolay Chudotvorets
    St. Petersburg, 190121, Russian Federation
  • City Psychiatric Hospital #4
    St. Petersburg, 191119, Russian Federation
  • SPHI "City Mental Hospital #3 n.a. I.I.Skvortsov-Stepanov"
    St. Petersburg, 197341, Russian Federation
  • FSBI "Research Institute for Mental Health" of Siberian branch of RAMS
    Tomsk, 634014, Russian Federation
  • Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
    Bojnice, 97201, Slovakia
  • Univerzitna nemocnica Bratislava, Nemocnica Ruzinov
    Brastislava, 82605, Slovakia
  • Psychiatricka nemocnica Hronovce
    Hronovce, 93561, Slovakia
  • Psychiatricka nemocnica Michalovce, n.o.
    Michalovce, 071 01, Slovakia
  • Vseobecna nemocnica Rimavska Sobota
    Rimavska Sobota, 97901, Slovakia
  • Nemocnica s poliklinikou sv. Barbory Roznava a.s.
    Roznava, 04801, Slovakia
  • Donetsk M. Gorkyi NMU Ch of Psychiatry, Narcology and MP CT&PI RCPsH
    Donetsk, 83008, Ukraine
  • Regional Psychoneurological Hospital #3
    Ivano-Frankivsk, 76014, Ukraine
  • SMPI Central Clinical Hospital of Ukrzaliznytsia
    Kharkiv, 61103, Ukraine
  • CI Kherson Regional Psychiatric Hospital of Kherson RC
    Kherson,Vil. Stepanivka, 73488, Ukraine
  • Kyiv City Clinical Psychoneurological Hospital #1
    Kyiv, 04080, Ukraine
  • Odesa Regional Psychoneurogical Dispensary
    Odesa, 65014, Ukraine
  • SI S.I. Heorhievskyi CSMU Ch of PPN with the Course of G&MP CRI CPH #1
    Simferopol, 95006, Ukraine
  • M.I. Pyrogov VNMU Ch of Psych&Nar BO CI O.I. Yuschenko VRPsH
    Vinnytsia, 21005, Ukraine
09

References and documents

Publications

  • Loebel A, Silva R, Goldman R, Watabe K, Cucchiaro J, Citrome L, Kane JM. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study. J Clin Psychiatry. 2016 Dec;77(12):1672-1680. doi: 10.4088/JCP.16m10698. PubMed 27454547 ↗
  • Loebel A, Citrome L, Correll CU, Xu J, Cucchiaro J, Kane JM. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. BMC Psychiatry. 2015 Oct 31;15:271. doi: 10.1186/s12888-015-0629-0. PubMed 26521019 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2013
First posted
Apr 1, 2013
Start
May 2013
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Jan 8, 2016
Last update
Jul 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01821378
Responsible party
Sponsor
First posted
Apr 1, 2013
Start date
May 2013
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Jan 8, 2016
Last update
Jul 21, 2016

Study contacts

Lurasidone Medical Director
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion